Stockscreener 앱 받기
28.41
2.20%
-0.64
시간 외 거래:
27.85
-0.56
-1.97%
전일 마감가:
$29.05
열려 있는:
$28.86
하루 거래량:
4.27M
Relative Volume:
0.76
시가총액:
$20.43B
수익:
$8.26M
순이익/손실:
$-397.91M
주가수익비율:
-56.41
EPS:
-0.5036
순현금흐름:
$-758.56M
1주 성능:
-1.01%
1개월 성능:
-0.53%
6개월 성능:
+40.37%
1년 성능:
+149.87%
1일 변동 폭
$28.32
$29.39
1주일 범위
$28.29
$29.64
52주 변동 폭
$10.71
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.41 | 20.89B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Outperform |
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey
ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView
ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with a 36.60% Potential Upside - DirectorsTalk Interviews
10 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Roivant Sciences’ $2.25 Billion Moderna Settlement: Can Pipeline Momentum Follow? - Smartkarma
Precision Trading with Roivant Sciences Ltd. (ROIV) Risk Zones - Stock Traders Daily
ROIV: Late-stage pipeline advances and imminent DM launch set up multiple catalysts for the year - TradingView
ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Did Roivant’s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy? - simplywall.st
Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside - DirectorsTalk Interviews
Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN
Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum - simplywall.st
Roivant Sciences Ltd.Common Shares (NQ: ROIV - FinancialContent
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ROIV Maintained by Guggenheim -- Price Target Raised to $36.00 - GuruFocus
Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing - Moomoo
Technical Reactions to ROIV Trends in Macro Strategies - Stock Traders Daily
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - simplywall.st
TD Cowen Raises its Price Target on Roivant Sciences (ROIV) - Insider Monkey
Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) - Yahoo Finance
Today's Analyst Rating | Roivant Sciences Price Target Raised to $31.5 by BofA Securities, UBS Downgrades Millicom International Cellular to Hold - Moomoo
Roivant Sciences Ltd. (ROIV) - DirectorsTalk Interviews
Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm
Roivant Sciences (ROIV) Slips Nearly 3% as Shares Test Key Support ZoneDealer Delta - thelegaladvocate.com
[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo
ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa
ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus
MSN Money - MSN
Roivant Sciences Is Maintained at Buy by Citigroup - Moomoo
ROIV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $34 - GuruFocus
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
Piper Sandler reiterates Roivant Sciences stock rating on trial progress By Investing.com - Investing.com Australia
Leerink raises Roivant Sciences stock price target on drug data By Investing.com - Investing.com South Africa
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
May 22 '26 |
Sale |
30.27 |
200,000 |
6,054,000 |
1,613,063 |
2.09%
0.40%
자본화:
|
볼륨(24시간):